Second primary tumor after immune checkpoint inhibitor therapy: A case report-Reference-Cited by-同舟云学术

Second primary tumor after immune checkpoint inhibitor therapy: A case report

Published:2022-02-11 Issue:7 Volume:13 Page:1076-1078
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Miao Kang¹,Yu Shuangni²,Ni Jun¹^ORCID,Zhang Xiaotong¹^ORCID,Zhang Li¹^ORCID

Affiliation:

1. Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital Chinese Academy of Medical Science & Peking Union Medical College Beijing China

2. Department of Pathology, Peking Union Medical College Hospital Chinese Academy of Medical Science & Peking Union Medical College Beijing China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14327

Reference9 articles.

1. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

2. Risk of second primary cancer in oral squamous cell carcinoma

3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

4. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

5. The risk of second primary tumors in head and neck cancer: A systematic review

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers;Frontiers in Oncology;2023-10-25

2. Radiation-Associated Angiosarcoma as a Presentation of Disease Progression in a Patient on Immunotherapy for Metastatic Non-small Cell Lung Cancer;Cureus;2023-09-05

3. High incidence combination of multiple primary malignant tumors of the digestive system;World Journal of Gastroenterology;2022-11-07

4. Camrelizumab/rivoceranib;Reactions Weekly;2022-05